VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Pfizer Inc. vs Synopsys, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Pfizer Inc.
PFE · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Synopsys, Inc.
SNPS · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Synopsys, Inc.'s moat claims, evidence, and risks.
View SNPS analysisComparison highlights
- Moat score gap: Synopsys, Inc. leads (85 / 100 vs 58 / 100 for Pfizer Inc.).
- Segment focus: Pfizer Inc. has 5 segments (47.4% in Primary Care); Synopsys, Inc. has 2 segments (75.2% in Design Automation).
- Moat breadth: Pfizer Inc. has 8 moat types across 3 domains; Synopsys, Inc. has 5 across 2.
Primary market context
Pfizer Inc.
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Global
Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement
Innovator biopharma (R&D + manufacturing + commercialization)
47.4%
Synopsys, Inc.
Design Automation
Electronic design automation (EDA) software and silicon-to-systems simulation & analysis tools
Global
Semiconductor and systems companies (chip/system designers)
Software + hardware tooling provider / platform
75.2%
Side-by-side metrics
Moat coverage
Shared moat types
Pfizer Inc. strengths
Synopsys, Inc. strengths
Segment mix
Pfizer Inc. segments
Full profile >Primary Care
Oligopoly
Specialty Care
Oligopoly
Oncology
Competitive
Pfizer CentreOne
Competitive
Pfizer Ignite
Competitive
Synopsys, Inc. segments
Full profile >Design Automation
Oligopoly
Design IP
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.